A panacea for the Greek pharma tragedy
This article was originally published in Scrip
Executive Summary
Greece’s significant financial crisis is doubtless turning into a tragedy for patients and pharmaceutical companies alike. Recent moves by the government to enforce lower prices and subsequent threats by drug manufacturers (among them Leo Pharma, Novo Nordisk and Norgine) either of non-compliance or potential withdrawal of products could be the precursor to litigation. However, it may be possible to salvage the situation, impose the price cuts and still stay within the confines of EU law.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.